Annals of Oncology 14:1338-1339, 2003
© 2003 European Society for Medical Oncology
Editorial |
Anything in modulation?
University of Birmingham Clinical Trials Unit, Birmingham B15 2RR, UK
*E-mail: r.gray@bham.ac.uk
| The first 10% of the full text of this article appears below. |
This issue of Annals of Oncology sees a report of a trial by the Italian INTACC intergroup comparing folinic acid-modulated fluorouracil, combined with levamisole, with fluorouracil and levamisole alone [1]. This large trial (n = 1703) adds importantly to our knowledge of the value of folinic acid in the fluorouracil/folinic acid (FUFA) chemotherapy combination, which is now widely accepted as the standard regimen in colorectal cancer [2]. No statistically significant differences in terms of disease-free survival or overall survival were found from modulating the action of fluorouracil with folinic acid. However, the absence of a statistically significant difference does not of course establish lack of benefit. There were fewer deaths (32%